Abstract:Repurposing identified Food and Drug Administration‐approved drug‐biomarker combinations with high sensitivity and specificity. In a real‐world dataset, repurposing identified novel drug‐biomarker combinations in patients who were ineligible for standard therapies or biomarker‐matched trials. Preliminary functional validation was demonstrated for two drug‐biomarker combinations. Using The Cancer Genome Atlas data, the potential scope of repurposing was identified. Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. Methods Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO‐500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature. Variants of unknown significance were classified as potentially pathogenic using plausible mechanisms and computational prediction of pathogenicity. Gain of function (GOF) mutations were evaluated through repurposing databases Probe Miner (PM), Broad Institute Drug Repurposing Hub (Broad Institute DRH) and TOPOGRAPH. GOF mutations were repurposing events if identified in PM, not indexed in TOPOGRAPH and excluding mutations with a known Food and Drug Administration (FDA)‐approved biomarker. The computational repurposing approach was validated by evaluating its ability to identify FDA‐approved biomarkers. The total repurposable genome was identified by evaluating all possible gene‐FDA drug‐approved combinations in the PM dataset. Results The computational repurposing approach was accurate at identifying FDA therapies with known biomarkers (94%). Using next‐generation sequencing molecular reports (n = 94), a meaningful percentage of patients (14%) could have an off‐label therapeutic identified. The frequency of theoretical drug repurposing events in The Cancer Genome Atlas pan‐cancer dataset was 73% of the samples in the cohort. Conclusion A computational drug repurposing approach may assist in identifying novel repurposing events in cancer patients with no access to standard therapies. Further validation is needed to confirm a precision oncology approach using drug repurposing.

Accelerating Complex Disease Treatment through Network Medicine and GenAI: A Case Study on Drug Repurposing for Breast Cancer

Computationally repurposing drugs for breast cancer subtypes using a network-based approach

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations

Drug repurposing against breast cancer by integrating drug-exposure expression profiles and drug–drug links based on graph neural network

AI-DrugNet: A network-based deep learning model for drug repurposing and combination therapy in neurological disorders

A network medicine approach for identifying diagnostic and prognostic biomarkers and exploring drug repurposing in human cancer

Drug Repurposing for Cancer Treatment Through Global Propagation with a Greedy Algorithm in a Multilayer Network

Artificial intelligence, machine learning, and drug repurposing in cancer

Integrated Network Pharmacology Approach for Drug Combination Discovery: A Multi-Cancer Case Study

A foundation model for clinician-centered drug repurposing

DrugComboRanker: Drug Combination Discovery Based on Target Network Analysis

Predicting drug-disease associations by network embedding and biomedical data integration.

Application of network embedding and transcriptome data in supervised drug repositioning

Shared genetics between breast cancer and its predisposing diseases identify novel breast cancer treatment candidates

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

Network Medicine: A Potential Approach for Virtual Drug Screening

Generating Drug Repurposing Hypotheses through the Combination of Disease-Specific Hypergraphs

Informatics on Drug Repurposing for Breast Cancer.

EKGDR: An End-to-End Knowledge Graph-Based Method for Computational Drug Repurposing